Skip to main content

Central Clearing

For those of my readers not familiar with the lingo of the financial world, let me begin with a definition of clearing and then of a clearinghouse.

Clearing is the process by which transactions are reconciled, that is, money matched to the product or service it is purchasing. An institution that "clears" a transaction is also the institution that, in the first instance, runs the risk of default. Simple example: I make some large purchase with a check. The seller accepts my check in payment. In that case, in a common arrangement my bank would be the clearing party, and would bear that initial risk of default.  It is the bank, not the seller, and not in the first instance me either, who will be "out" if my check is in excess of my deposit account.

In finance, then, a clearinghouse (sometimes written in two words as 'clearing house') is an institution that provides clearing and settlement services for commodities, derivatives, or securities transactions.

The issue of whether a transaction will take place on or off a listed exchange is not the same as whether the transaction will be centrally cleared. The trend since the global financial crisis of 2007-08  has been toward ever more central clearing, even in off-exchange, aka over the counter or OTC, transactions. One of the many 'takes' on the crisis was that the absence of central clearing was to blame, and the governments of various developed countries including the US have been working to build up clearinghouses in contexts in which they were not necessarily considered desirable pre-crisis.

Craig Pirrong, finance professor at Bauer College of Business, University of Houston, lists four distinct questions raised by this trend, especially with reference to derivatives trading, thus:

1) Do we want to favor central clearing over bilateral arrangements? There are arguments in favor of the trend, but some bilateralism will surely remain, and the right balance is not at all self-evident;

2) How do different clearing mechanisms affect the allocation of risks, including non-obvious risks and indirect allocations thereof?

3) How will the rules change the scale of derivatives trading?

4) Will the rules, in Pirrong's terms, "affect risk management by end-users and what is the implication of that for the allocation of risk in the economy?"

That is a good list. Here's the link to Pirrong's discussion.


Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…